PerkinElmer and American Society of Hematology Announce Global Collaboration to Help Combat Sickle Cell Disease

WALTHAM, Mass., June 18, 2020 /PRNewswire/ -- PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced a collaboration with the American Society of Hematology (ASH), the world's largest professional society of hematologists, to support a new effort to increase capacity for newborn screening, education, and clinical interventions for sickle cell disease (SCD) in sub-Saharan Africa.

Roughly 120 million people globally have SCD, two-thirds of whom live in Africa, where a majority of children who have SCD die before the age of 5. Universal newborn screening for SCD, in practice in many high-income countries, does not exist in most of Africa. Early detection is critical to allow health care providers to begin effective treatment and improve long-term health outcomes of children with SCD.

Through this collaboration, PerkinElmer and ASH will enhance their efforts to bring SCD screening to countries in sub-Saharan Africa, investing resources to develop screening networks, education, clinical intervention, and advocacy through the Consortium on Newborn Screening in Africa (CONSA), a collaboration with African hematologists, public health authorities, and ASH dedicated to studying the benefits of newborn screening and early therapeutic interventions for SCD. CONSA introduces standard-of-care practices for screening and early intervention therapies (such as antibiotic prophylaxis and immunizations) with plans to screen 10,000-20,000 newborns per year in each sub-Saharan country and provide clinical follow-up for babies who screen positive for SCD.

"Through CONSA, we have the chance to show the long-term benefits of newborn screening and early interventions for sickle cell disease led by hematologists in Africa," said Dr. Enrico Novelli, MD, chief of the Section of Benign Hematology at the University of Pittsburgh and CONSA Co-Chair. Dr. Nancy Berliner, chief of the Division of Hematology at Harvard Medical School and CONSA Co-Chair added, "Clinical sites from countries in Africa are working with PerkinElmer and ASH to acquire the support and expertise needed to improve survival for children living with sickle cell disease; we want to demonstrate the value of these programs to encourage partners to scale up."

ASH President Dr. Stephanie Lee, MD, MPH, associate director of the Clinical Research Division at Fred Hutchinson Cancer Research Center, noted "Through collaboration with PerkinElmer, ASH's mission to understand, diagnose, treat, and prevent disorders of the blood will be expanded to key areas in Africa, even where health resources may be extremely limited. We are excited to see the positive effects of this partnership on the sustainability of routine newborn screening in Africa."

"Sickle cell disease is a serious, but treatable disease if detected early," remarked Petra Furu, GM, Reproductive Health, PerkinElmer. "While newborn screening for sickle cell disease is not new in North America and Europe, it hasn't been the norm across the globe. PerkinElmer has been a pioneer in testing for sickle cell disease that has altered the course of countless lives for the better and is poised to work with ASH to ensure screening for this disease becomes universal."

PerkinElmer is a global provider of hemoglobin isoelectric focusing (IEF) technology that helps detecting sickle cell disease. The company is also global provider in tests for more than 50 other inherited disorders in newborns used around the world.

About American Society of Hematology
The American Society of Hematology (ASH) (www.hematology.org) is the world's largest professional society of hematologists dedicated to furthering the understanding, diagnosis, treatment, and prevention of disorders affecting the blood. For more than 60 years, the Society has led the development of hematology as a discipline by promoting research, patient care, education, training, and advocacy in hematology.

In 2016, ASH launched a multifaceted initiative to address the burden of disease both in the United States and globally. ASH has since developed clinical guidelines for SCD management and care, expanded education and training efforts, advocated with policymakers to enhance and expand federal SCD programs, established a newborn screening consortium in sub-Saharan Africa, and founded the Sickle Cell Disease Coalition. In addition to these efforts, the ASH Research Collaborative (ASH RC) Data Hub and SCD Clinical Trials Network was developed with the mission to improve outcomes for individuals with SCD by expediting SCD therapy development and facilitating innovation in clinical trial research. It provides the infrastructure for identifying patient cohorts for trials, matching trial sponsors with sites, facilitating recruitment of eligible patients, and ensuring optimally designed trials and an efficient, coordinated approach. Through patient engagement and optimized clinical trial execution, the Clinical Trials Network will help to bring new and more effective therapies to individuals with SCD.

About PerkinElmer
PerkinElmer enables scientists, researchers, and clinicians to address their most critical challenges across science and healthcare. With a mission focused on innovating for a healthier world, we deliver unique solutions to serve the diagnostics, life sciences, food, and applied markets. We strategically partner with customers to enable earlier and more accurate insights supported by deep market knowledge and technical expertise. Our dedicated team of about 13,000 employees worldwide is passionate about helping customers work to create healthier families, improve the quality of life, and sustain the wellbeing and longevity of people globally. The Company reported revenue of approximately $2.9 billion in 2019, serves customers in 190 countries, and is a component of the S&P 500 index. Additional information is available through 1-877-PKI-NYSE, or at www.perkinelmer.com.

Factors Affecting Future Performance 
This press release contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to estimates and projections of future earnings per share, cash flow and revenue growth and other financial results, developments relating to our customers and end-markets, and plans concerning business development opportunities, acquisitions and divestitures. Words such as "believes," "intends," "anticipates," "plans," "expects," "projects," "forecasts," "will" and similar expressions, and references to guidance, are intended to identify forward-looking statements. Such statements are based on management's current assumptions and expectations and no assurances can be given that our assumptions or expectations will prove to be correct. A number of important risk factors could cause actual results to differ materially from the results described, implied or projected in any forward-looking statements. These factors include, without limitation: (1) markets into which we sell our products declining or not growing as anticipated; (2) fluctuations in the global economic and political environments; (3) our failure to introduce new products in a timely manner; (4) our ability to execute acquisitions and license technologies, or to successfully integrate acquired businesses and licensed technologies into our existing business or to make them profitable, or successfully divest businesses; (5) our failure to adequately protect our intellectual property; (6) the loss of any of our licenses or licensed rights; (7) our ability to compete effectively; (8) fluctuation in our quarterly operating results and our ability to adjust our operations to address unexpected changes; (9) significant disruption in third-party package delivery and import/export services or significant increases in prices for those services; (10) disruptions in the supply of raw materials and supplies; (11) the manufacture and sale of products exposing us to product liability claims; (12) our failure to maintain compliance with applicable government regulations; (13) regulatory changes; (14) our failure to comply with healthcare industry regulations; (15) outbreaks of communicable diseases such as COVID-19; (16) economic, political and other risks associated with foreign operations; (17) our ability to retain key personnel; (18) significant disruption in our information technology systems, or cybercrime; (19) our ability to obtain future financing; (20) restrictions in our credit agreements; (21) discontinuation or replacement of LIBOR; (22) the United Kingdom's withdrawal from the European Union; (23) our ability to realize the full value of our intangible assets; (24) significant fluctuations in our stock price; (25) reduction or elimination of dividends on our common stock; and (26) other factors which we describe under the caption "Risk Factors" in our most recent annual report on Form 10-K and in our other filings with the Securities and Exchange Commission. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

View original content to download multimedia:http://www.prnewswire.com/news-releases/perkinelmer-and-american-society-of-hematology-announce-global-collaboration-to-help-combat-sickle-cell-disease-301079632.html

SOURCE American Society of Hematology